Skip to main content
. 2022 Jan 29;15(2):171. doi: 10.3390/ph15020171

Figure 2.

Figure 2

VEGF-modified GelMA hydrogel. (a) Handheld printing using VEGF-modified GelMA hydrogel as bioink for wound healing (left) and immunostained for von Willebrand Factor under an optical microscope (right) with quantitative results of wound bed angiogenesis by measurement of vWF signal in different wounds (n = 6). The data is presented as mean ± standard error of mean (SEM). Comparison of the different groups was performed using a student’s T test and * represents p < 0.0005 (bottom left). (b) Schematic illustration of GelMA-microneedles loaded with AAV-VEGF and the results of cerebral ischemia treatment in rats among different groups treated. (Photothrombotic (PT), microneedle (MN), adeno-associated virus (AAV), vascular endothelial growth factor loaded microneedle (MN-VEGF)). Statistical analysis was performed using a two-sided Student’s t-test or one-way analysis of variance (ANOVA). of the infarct area (upper right) and the protein levels of VEGF in the brain 3 weeks after MN implantation (lower right). The data are expressed as the mean ± SD. * p < 0.05 and **** p < 0.0001. Reproduced (adapted) with permission from Ref. [23]. 2022 © Biomaterials, and from Ref. [27]. 2021 © Journal of Controlled Release.